Post-evolutionary Biologics
Accipiter Biosciences designs and develops de novo protein therapies — unbound by natural limitations — to address the world’s most complex diseases. Our single-agent biologics are custom-engineered to engage multiple pathways without the limitations of traditional combination therapies.
Complex diseases need a new approach
Complex diseases like autoimmune disorders and cancer are challenging to treat because they have multiple underlying causes within the body. Increasingly, these diseases are managed with combination therapies that are intended to target multiple molecular pathways.
However, there are downsides to drug combinations. It costs more money and takes longer to develop and test drug combinations. For patients, taking several medicines can be more difficult and less convenient. Combinations can sometimes cause unwanted side effects.
Most important, if there are differences in the way the drugs act or move through the body, they may never act together in the right place or at the same time.
At Accipiter, we’re using computational protein design to find a new way to treat complex diseases.
Multiple therapeutic mechanisms in one stable protein
Our de novo biologics combine multiple mechanisms in one stable protein molecule. These therapeutic candidates are purpose-built to activate more than one cell-surface receptor — on the same cell at the same time.
Unlike antibodies and multispecifics, which block cell pathways, our biologics can function as agonists, activating cell pathways.
Our versatile platform
Using novel computational methods, we create fully customizable, multifunctional proteins for any therapeutic application. The speed of in silico methods means we can go from design to testing in the lab in less than 2 months.
How it works
Design a new protein concept
Run proprietary computer models to generate a protein sequence
Express and purify the protein in the lab
Test the protein activity in vitro and in vivo